Eupraxia Pharmaceuticals: Underdiagnosed EoE Market Expands Upside, Supporting Buy Rating on EPRX

Bloom Burton analyst David Martin PhD maintained a Buy rating on Eupraxia Pharmaceuticals today and set a price target of $14.00.

David Martin PhD has given his Buy rating due to a combination of factors related to Eupraxia’s lead opportunity in Eosinophilic Esophagitis and the evolving view of that market. The recent KOL call with Dr. Evan Dellon highlighted that current prevalence estimates likely undercount the true number of EoE patients, implying a substantially larger treatable population than generally appreciated.

This underdiagnosis, including hundreds of thousands of U.S. patients presenting to emergency rooms with EoE-like symptoms but rarely being properly identified, supports the potential for robust demand if effective, convenient therapies are approved. Martin therefore sees meaningful upside to Eupraxia’s addressable market assumptions and, by extension, to the company’s revenue and valuation outlook, supporting a Buy recommendation on EPRX.

In another report released on March 23, William Blair also initiated coverage with a Buy rating on the stock with a $14.00 price target.

Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPRX in relation to earlier this year.